Last updated: 2026-05-09

RxGrab Research

RxGrab publishes original research on prescription drug pricing reality. Our studies combine our first-party drug database with patent expiry data, wholesale pricing pulls, and crowdsourced retail pricing.

Published research

2026-11-13 · dataset

Generic Drug Price Cliff 2013-2026: How Acquisition Cost Moves After the First Generic Approval, 200 Drugs

Two years after the first generic approval, the median product's acquisition cost is 80% of its first observed price; after five years 46%; after ten 22%. The spread is wide: after ten years the middle half of products runs from 5% to 53%. A pattern in matched products, not a causal estimate.

DOI: 10.5281/zenodo.24182324 Licence: CC BY 4.0

2026-11-13 · dataset

CMS NADAC Year-End Acquisition Cost History 2013 to 2026: What Pharmacies Paid per Unit for 10,979 Products

Between the 2014 and 2026 year-end surveys, among 1,214 generic products priced from at least 3 NDCs at both ends, the median acquisition cost is 46% of its 2014 level and 658 fell by half or more; among 33 brand products the median is 174%. Counts of CMS's survey as of the stated weeks.

DOI: 10.5281/zenodo.24182320 Licence: CC BY 4.0

2026-05-09 · published

Brand-to-Generic Patent Cliff 2026: 50 Drugs, Post-Generic Price Decay, and the Stalled-Generic Cases That Never Got Cheaper

Audit of 50 drugs across patent expiry transitions cross-referenced with FDA Orange Book, USPTO patents, and ASPE pricing data. 45 have approved generics; 5 are pending the cliff (Ozempic, Wegovy, Jardiance, Eliquis, Xarelto). Cross-referenced with FTC Pay-for-Delay, CMS IRA, KFF Medicare Part D, and Mark Cuban Cost Plus public pricing. Editorial review pending PharmD partner.

Dataset: 50 drugs Primary sources: FDA Orange Book, Drugs@FDA, USPTO, CMS NADAC, FTC Pay-for-Delay, CBO IRA, GAO-19-498, IQVIA, RAND RR-A788-1, KFF, AAM, Mark Cuban Cost Plus

How we work

Every study ships with full methodology disclosure: dataset size, time range, exclusions, and source attribution. Surveys disclose sample size, recruitment platform, and demographic stratification. We publish raw data alongside the analysis under a Creative Commons Attribution 4.0 license so researchers, journalists, and operators can verify our claims and build on the work.

We do not run sponsored research, paid placements, or vendor-funded studies. Every study is funded directly by RxGrab as part of its independent editorial mission.

Press and citations

Journalists, researchers, and operators are welcome to cite our findings under CC-BY 4.0 with attribution. For interviews, exclusive embargoed access, or additional data cuts, contact vincent@deepsynthesis.org.

Each study includes a press kit at its /press/ subpage with quotable findings, downloadable charts, and methodology summaries. Embargo requests honored when received at least 72 hours before scheduled publication.

All RxGrab research is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). Attribution required: link to the study URL or to rxgrab.com/research/.